Cargando…

Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma

C–C motif chemokine ligand 2 (CCL2) is a monocyte chemoattractant that promotes metastatic disease and portends a poor prognosis in many cancers. To determine the potential of anti-CCL2 inhibition as a therapy for recurrent metastatic disease in neuroblastoma, a mouse model of minimal residual disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lascano, Danny, Zobel, Michael J., Lee, William G., Chen, Stephanie Y., Zamora, Abigail, Asuelime, Grace E., Choi, So Yung, Chronopoulos, Antonios, Asgharzadeh, Shahab, Marachelian, Araz, Park, Jinseok, Sheard, Michael A., Kim, Eugene S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645976/ https://www.ncbi.nlm.nih.gov/pubmed/37964011 http://dx.doi.org/10.1038/s41598-023-46968-2

Ejemplares similares

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2
por: Metelitsa, Leonid S., et al.
Publicado: (2004)

Distinct effects of etoposide on glutamine-addicted neuroblastoma
por: Valter, Kadri, et al.
Publicado: (2019)

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1
por: Xu, Yibing, et al.
Publicado: (2013)

Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL
por: Kim, Hye Ryung, et al.
Publicado: (2012)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC
por: Hadjidaniel, Michael D., et al.
Publicado: (2017)

Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma
por: Shirinbak, Soheila, et al.
Publicado: (2021)

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
por: Marachelian, Araz, et al.
Publicado: (2016)

17230 Agreement between point-of-care intestinal ultrasound (POCUS) and magnetic resonance enterography for assessment of the terminal ileum through sigmoid colon in pediatric patients with inflammatory bowel diseases: A diagnostic cross-sectional study
por: Chavannes, Mallory, et al.
Publicado: (2021)

Dedifferentiated endometrioid adenocarcinoma with trophoblastic components: Prolonged remission after treatment with bleomycin, etoposide, and cisplatin
por: Martin, Alexa K., et al.
Publicado: (2020)

Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells
por: Wang, Guan, et al.
Publicado: (2013)

PKCα Inhibition as a Strategy to Sensitize Neuroblastoma Stem Cells to Etoposide by Stimulating Ferroptosis
por: Monteleone, Lorenzo, et al.
Publicado: (2021)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
por: Kang, Min H, et al.
Publicado: (2014)

Synthesis of Polystyrene-Based Cationic Nanomaterials with Pro-Oxidant Cytotoxic Activity on Etoposide-Resistant Neuroblastoma Cells
por: Alfei, Silvana, et al.
Publicado: (2021)

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.
por: Lee, C. R., et al.
Publicado: (1993)

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
por: Moghimi, Babak, et al.
Publicado: (2021)

p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment
por: Marengo, B, et al.
Publicado: (2013)

Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants
por: Eberhard, Yanina, et al.
Publicado: (2004)

Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma
por: Lalchungnunga, H., et al.
Publicado: (2022)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
por: Wu, Chunsheng, et al.
Publicado: (2020)

Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic and Pro-Oxidant Effect on Human Neuroblastoma Cells
por: Alfei, Silvana, et al.
Publicado: (2020)

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)

PKCδ Sensitizes Neuroblastoma Cells to L-Buthionine-Sulfoximine and Etoposide Inducing Reactive Oxygen Species Overproduction and DNA Damage
por: Marengo, Barbara, et al.
Publicado: (2011)

Molecular mechanisms of etoposide
por: Montecucco, Alessandra, et al.
Publicado: (2015)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023)

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
por: Warner, E., et al.
Publicado: (1998)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas
por: Galenkamp, Koen MO, et al.
Publicado: (2015)

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
por: Gong, Baocheng, et al.
Publicado: (2021)

Differential Gene and MicroRNA Expression between Etoposide Resistant and Etoposide Sensitive MCF7 Breast Cancer Cell Lines
por: Moitra, Karobi, et al.
Publicado: (2012)

Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP).
por: Rubie, H., et al.
Publicado: (1998)

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
por: Gong, Baocheng, et al.
Publicado: (2022)

Emerging role of bacterial extracellular vesicles in cancer
por: Chronopoulos, Antonios, et al.
Publicado: (2020)

The effect of etoposide on human CFU-GM.
por: Bailey-Wood, R., et al.
Publicado: (1985)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hb2pfu0tb2hqb6lpep59e4m56f